Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

被引：12
|
作者：
Hifumi, Toru [1 ]
Isokawa, Shutaro [1 ]
Otani, Norio [1 ]
Ishimatsu, Shinichi [1 ]
机构：
[1] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
来源：
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词：
COVID-19; Adverse events; Nafamostat mesylate; Favipiravir;
D O I：
10.1186/s13054-020-03227-4
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment
    Ozturk, Servet
    Colak, Onur
    Kavas, Semra
    Ozturk Engin, Derya
    Diktas Tahtasakal, Serap
    Erdogan Ari, Dilek
    Demiroluk, Oznur
    Ozdemir, Berna
    Cetinkaya, Busra Meral
    Kacar Eker, Merve
    Dogan, Irem Asena
    Vahaboglu, Haluk
    Agalar, Canan
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2021, 10
  • [42] Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19
    Irie, Kei
    Nakagawa, Atsushi
    Fujita, Hirotoshi
    Tamura, Ryo
    Eto, Masaaki
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Tomii, Keisuke
    Hashida, Tohru
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (05): : 880 - 885
  • [43] Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19
    Amani, Behnam
    Zareei, Sara
    Amani, Bahman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (10) : 4403 - 4411
  • [44] The effects of favipiravir on hematological parameters of covid-19 patients
    Yaylaci, Selcuk
    Dheir, Hamad
    Senocak, Didar
    Genc, Ahmed Bilal
    Kocayigit, Havva
    Cekic, Deniz
    Varim, Ceyhun
    Aydin, Abdulkadir
    Koroglu, Mehmet
    Karabay, Oguz
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 : 65 - 70
  • [45] Favipiravir exposure and pregnancy outcome of COVID-19 patients
    Tirmikcioglu, Zeynep
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 268 : 110 - 115
  • [46] Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
    Henrietta Papp
    Zsófia Lanszki
    György M. Keserű
    Ferenc Jakab
    GeroScience, 2022, 44 : 1263 - 1268
  • [47] Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
    Ikeda, Mahoko
    Okugawa, Shu
    Kashiwabara, Kosuke
    Moritoyo, Takashi
    Kanno, Yoshiaki
    Jubishi, Daisuke
    Hashimoto, Hideki
    Okamoto, Koh
    Tsushima, Kenji
    Uchida, Yasuki
    Mitsumura, Takahiro
    Igari, Hidetoshi
    Tsutsumi, Takeya
    Araoka, Hideki
    Yatera, Kazuhiro
    Yamamoto, Yoshihiro
    Nakamura, Yuki
    Otani, Amato
    Yamashita, Marie
    Wakimoto, Yuji
    Shinohara, Takayuki
    Adachi-Katayama, Maho
    Oyabu, Tatsunori
    Kanematsu, Aoi
    Harada, Sohei
    Takeshita, Yuichiro
    Nakano, Yasutaka
    Miyazaki, Yasunari
    Sakao, Seiichiro
    Saito, Makoto
    Ogura, Sho
    Yamasaki, Kei
    Kawasuji, Hitoshi
    Hataji, Osamu
    Inoue, Jun-Ichiro
    Seto, Yasuyuki
    Moriya, Kyoji
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 128 : 355 - 363
  • [48] Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19
    Zengin, Rehile
    Sarikaya, Zeynep Tugce
    Karadag, Nalan
    Cuhadaroglu, Caglar
    Ergonul, Oender
    Kocagoz, Sesin
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2020, 2 (01): : 24 - 26
  • [49] Severe sinus bradycardia associated with favipiravir in a COVID-19 patient
    Habib, Mhd Baraa
    Elshafei, Mohamed
    Rahhal, Alaa
    Mohamed, Mouhand F. H.
    CLINICAL CASE REPORTS, 2021, 9 (08):
  • [50] Signaling COVID-19 Vaccine Adverse Events
    Rave Harpaz
    William DuMouchel
    Robbert Van Manen
    Alexander Nip
    Steve Bright
    Ana Szarfman
    Joseph Tonning
    Magnus Lerch
    Drug Safety, 2022, 45 : 765 - 780
12345